semaglutide우선순위 중간ICSR 검토기타
LITERATURE DETAIL · PMID 42251859
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.
- 저자
- John B Buse, Harpreet S Bajaj, Stine-Mathilde Dalskov, Lucienne Donaldson, Helene H Hansen Duus, Therese Wilbek Fabricius
- 저널
- The lancet. Diabetes & endocrinology
- 공개일
- 2026 Aug
- 연구 유형
- 기타
- DOI
- 10.1016/S2213-8587(26)00125-7
문헌 요약
The amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide have complementary effects on glycaemic control and bodyweight. We aimed to investigate the efficacy and safety of a fixed-dose combination of cagrilintide and semaglutide (cagrilintide-semaglutide; known as CagriSema) versus semaglutide or cagrilintide for glycaemic contr…
PV 검토 포인트
개별 증례 가능성과 중대성, 예상성 및 중복 여부를 우선 검토합니다.